The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients.
Marina B. Stenina
No relevant relationships to disclose
Ekaterina Ignatova
No relevant relationships to disclose
Mona A. Frolova
No relevant relationships to disclose
Olga N. Burdaeva
No relevant relationships to disclose
Marina P. Nechaeva
No relevant relationships to disclose
Mikhail V. Kopp
No relevant relationships to disclose
Dmitry P. Udovitsa
No relevant relationships to disclose
Bogdan N. Kotiv
No relevant relationships to disclose
Sergiy M. Alekseev
No relevant relationships to disclose
Daniil L. Stroyakovsky
No relevant relationships to disclose
Ludmila P. Sheveleva
No relevant relationships to disclose
Andrey V. Khorinko
No relevant relationships to disclose
Tatiana I. Prokopenko
No relevant relationships to disclose
Julia S. Shapovalova
No relevant relationships to disclose
Irina A. Jelvakova
No relevant relationships to disclose
R. Ivanov
No relevant relationships to disclose
Olga V. Filon
No relevant relationships to disclose
Sergei Tjulandin
No relevant relationships to disclose